Robert Doebele - 09 Aug 2023 Form 4 Insider Report for Rain Oncology Inc.

Role
President, Chief Scientific Officer
Signature
/s/ Avanish Vellanki, Attorney-in-fact for Robert Doebele
Issuer symbol
N/A
Transactions as of
09 Aug 2023
Net transactions value
$0
Form type
4
Filing time
11 Aug 2023, 21:16:15 UTC
Previous filing
17 Feb 2023
Next filing
26 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RAIN Stock Option (Right to Buy) Award $0 +99,400 $0.000000 99,400 09 Aug 2023 Common Stock 99,400 $1.21 Direct F1
transaction RAIN Stock Option (Right to Buy) Award $0 +49,700 $0.000000 49,700 09 Aug 2023 Common Stock 49,700 $1.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 99,400 shares of the Issuer's common stock, which will vest in equal installments on May 9, 2024 and February 9, 2025, subject to the Reporting Person's continued service to the Issuer.
F2 This option represents a right to purchase a total of 49,700 shares of the Issuer's common stock, which will vest in equal installments on May 9, 2024 and February 9, 2025, subject to the achievement of certain corporate goals and the Reporting Person's continued service to the Issuer.

Remarks:

President, Chief Scientific Officer